Panacea, Sanofi settle patent litigation over hexavalent vaccine
Panacea Biotec on Tuesday said it has entered into a settlement with Sanofi Healthcare India Private Limited in a patent infringement litigation over hexavalent vaccine.
Under the terms of settlement agreement, Sanofi has agreed that at present it would not commercially launch its fully liquid hexavalent vaccine Shan6 in India and shall also withdraw the opposition filed against Panacea Biotec’s patent IN 272351 on hexavalent vaccine before the Indian Patent Office.
In turn, Panacea Biotec has agreed to forgo its claim for damages and rendition of accounts in the proceedings against Sanofi.
«We are pleased to inform that the parties have reached a settlement agreement, and pursuant to the joint application filed by the Parties, the said suit has been disposed of by the Hon’ble Delhi High Court on September 13, 2024,» Panacea Biotec told in a statement.
The patent suit was filed by Panacea Biotec against Sanofi in May 2021 after the latter received marketing approval for a Shan6, a whole cell Pertussis based hexavalent vaccine (DTwP-HepB-Hib-IPV) by the Drugs Controller General (India).
Artificial Intelligence(AI)
Java Programming with ChatGPT: Learn using Generative AI
By — Metla Sudha Sekhar, Developer and Lead Instructor
Artificial Intelligence(AI)
Basics of Generative AI: Unveiling Tomorrow's Innovations
By — Metla Sudha Sekhar, Developer and Lead Instructor
Artificial Intelligence(AI)
Generative AI for Dynamic Java Web Applications with ChatGPT
By — Metla Sudha Sekhar, Developer and Lead Instructor
Artificial
